Deucravacitinib in moderate‐to‐severe plaque psoriasis: Pooled safety and tolerability over 52 weeks from two phase 3 trials (<scp>POETYK PSO</scp>‐1 and <scp>PSO</scp>‐2)

Abstract

Deucravacitinib was well-tolerated with acceptable safety over 52 weeks in patients with psoriasis.